Bifunctional Compounds Targeting SMARCA2 via VHL E3 Ligase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches, such as SMARCA4 bromodomain inhibitors, exhibit limited efficacy in inhibiting SMARCA2 and SMARCA4-related cancers, highlighting the need for alternative strategies to target these proteins effectively.
Innovation Solution
Development of bifunctional compounds comprising a target protein binding moiety and an E3 ubiquitin ligase binding moiety, specifically designed to modulate ubiquitination of SMARCA2, facilitating its degradation and inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SMARCA4 bromodomain inhibitors are used to target SMARCA2 and SMARCA4, then some inhibition effect is achieved, but the efficacy is limited and insufficient for effective cancer treatment
Solution Approach 1:
The bifunctional compound is divided into two distinct functional moieties: a SMARCA2 binding moiety (A′) and a VHL E3 ubiquitin ligase binding moiety (B), connected by a linker (L). This segmentation allows each moiety to independently perform its function - SMARCA2 binding and E3 ligase recruitment - thereby achieving more effective target engagement and protein degradation compared to single-function inhibitors
Solution Approach 2:
The linker (L) serves as an intermediary component connecting the SMARCA2 binding moiety and the VHL binding moiety. This intermediary structure enables the bifunctional compound to bridge the target protein and the E3 ubiquitin ligase, facilitating their interaction and subsequent ubiquitination of SMARCA2, which monofunctional inhibitors cannot achieve
2Reliability
If gene expression manipulation such as RNAi is used to downregulate SMARCA2, then strong synthetic lethality and cancer cell proliferation suppression are achieved, but small molecule-based approaches like bromodomain inhibitors fail to produce similar effects
Solution Approach 1:
The invention changes the mechanism of action from simple binding (bromodomain inhibition) to induced protein degradation via the ubiquitin-proteasome system. By incorporating the VHL E3 ubiquitin ligase binding moiety, the compound triggers a cascade of biochemical events (ubiquitination) that lead to complete protein degradation, achieving efficacy comparable to RNAi but through a small molecule approach
3Reliability
If SMARCA2 is targeted for degradation in SMARCA4-deficient cancers, then therapeutic benefit is expected, but achieving specific and effective degradation requires complex bifunctional design
Solution Approach 1:
The bifunctional compound integrates multiple functions into a single molecular entity: SMARCA2 binding, VHL E3 ligase binding, and linker-mediated connectivity. This multi-functional design enables the compound to simultaneously engage the target protein and the degradation machinery, achieving specific and effective SMARCA2 degradation in SMARCA4-deficient cancers while maintaining a manageable structural complexity through modular construction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively target SMARCA2, offering a promising therapeutic approach for SMARCA4-deficient cancers by enhancing protein degradation, potentially leading to improved cancer cell proliferation suppression.
Implementation Method 1
bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, specifically designed to modulate ubiquitination of SMARCA2, facilitating its degradation
Data Source
AI summary
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.